新辅助化疗不同疗程数对晚期上皮性卵巢癌患者近远期疗效的影响分析-现代医学

新辅助化疗不同疗程数对晚期上皮性卵巢癌患者近远期疗效的影响分析

单位：东部战区总医院秦淮医疗区妇科, 江苏南京 210002

分类号：R737.31

出版年·卷·期（页码）：2023·51·第四期（513-517）

摘要：

目的:研究新辅助化疗(NACT)不同疗程数对晚期上皮性卵巢癌的近期以及远期疗效的影响。方法:回顾性分析2015年1月至2018年12月在我科接受NACT联合间歇性肿瘤细胞减灭术(NACT-IDS)治疗的晚期上皮性卵巢癌的患者42例，按NACT疗程数分为4组，2周期为G1组，3周期为G2组，4周期为G3组，≥5周期为G4组。观察各组患者近期疗效指标以及远期疗效，其中近期疗效指标包括NACT前后血清肿瘤标记CA125水平变化情况，无肉眼可见残留病灶(R0)比率、病理缓解情况；远期疗效指标包括中位无进展生存期(PFS)、总生存期(OS)情况。结果:前3组(G1、G2、G3)NACT后肿瘤标记CA125水平下降＞90%，各组间比较差异无统计学意义(P＞0.05)；G4组肿瘤标记下降＜80%，与前3组比较，差异有统计学意义(P＜0.05)。G4组的R0比率以及病理缓解率均较前3组明显下降(P＜0.05)；前3组间比较，差异无统计学意义(P＞0.05)。G4组患者的PFS及OS均较前3组缩短(P＜0.05)；前3组的PFS、OS比较，差异无统计学意义(P＞0.05)。结论:通过分析不同NACT疗程数对晚期上皮性卵巢癌患者近期以及远期疗效的影响，有助于指导临床选择合适的手术时机，改善患者预后，避免过多NACT疗程给患者预后带来负面影响。

Objective: To study the impact of different courses of neoadjuvant chemotherapy(NACT) on the short-term and long-term efficacy of advanced epithelial ovarian tumor. Methods: A retrospective analysis was conducted of 42 patients with advanced epithelial ovarian tumor who received NACT followed by intermittent tumor ablation(NACT-IDS) in our department from January 2015 to December 2018.According to the number of courses of NACT, they were divided into 4 groups: G1 group for 2 cycles, G2 group for 3 cycles, G3 group for 4 cycles, and G4 group for ≥5 cycles. The short-term and long-term therapeutic effects of patients in each group were observed. The short-term efficacy included changes of serum tumor marker CA125 levels before and after NACT, ratio of R0 without gross residual tumor, and pathological remission; long term efficacy indicators include progression-free survival(PFS) and overall survival(OS). Results: After NACT, the level of tumor marker CA125 in former three groups(G1, G2, G3) decreased by more than 90%, and there was no significant difference among these groups(P>0.05); The tumor markers in G4 group decreased by<80%, which was statistically different from the former three groups(P<0.05). The R0 ratio and pathological remission rate in G4 group were significantly lower than those in the former three groups(P<0.05); There was no significant difference among the former three groups(P>0.05). PFS and OS in G4 group were lower than those in the former three groups(P<0.05); There was no significant statistical difference between PFS and OS in the former three groups(P>0.05). Conclusion: By analyzing the impact of different NACT courses on the short-term and long-term outcomes of patients with advanced epithelial ovarian tumor, it is helpful to guide the clinical selection of appropriate surgical opportunities, improve the prognosis of patients, and avoid the negative impact of excessive neoadjuvant chemotherapy courses on the prognosis of patients.

参考文献：

[1] ZHAO D,WU L Y,WANG X B,et al.Role of neoadjuvant chemothreapy in the management of advanced oarian cancer[J].Asian Pac J Cancer Prev,2015,16(6):2369-2373.
[2] 葛录倩,孙文洲,赵欣瑶,等.新辅助化疗联合间隔肿瘤细胞减灭术对晚期卵巢癌耐药性和生存时间的影响及耐药影响因素分析[J].实用妇产科杂志，2017,33(1):43-47.
[3] KAIPIO K,CHEN P,ROERING P,et al.ALDH1A1-related stemness in high-grade serous oravrian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors[J].J pathol,2020,250(2):159-169.
[4] ZHANG G N,LIU H,HUANG J M,et al.TP53 K351Nmutation-associated platinnum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer[J].Gynecol Oncol,2014,132(3):752-757.
[5] KESS R,LASKOV I,ABITBOL J,et al.Clinical outcome of neoadjuvant chemotherapy for advanced ovarian cancer[J].Gynecol Oncol,2017,144(3):474-479.
[6] NISHIO S,USHIJIMA K.Clinical significance of primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery in advanced ovarian[J].JPN J Clin Oncol,2020,50(4):379-386.
[7] BLOCK M S,VIERKAN R A,RAMBAU P F,et al.MyD88 and TLR4 expression in epithelial ovarian cancer[J].Mayo Clin Proc,2018,93(3):307-320.
[8] 张国楠,朱熠,黄建鸣.紫杉醇在上皮性卵巢癌化疗中的双刃剑效应与对策思考[J].中国实用妇科与产科杂志，2017,33(1)：21-24.
[9] LOIZZI V,CORMIO G,RESTA L,et al.Neoadjuvant chemotherapy in advanced ovarian cancer:a case-control study[J].Int J Gynecol Cancer,2005,15(2):217-223.
[10] LE T,WILLIAMS K,SENTERMAN M,et al.Histopathologic assessment of chemotherapy effects in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgicaldebulking[J].Gynocol Oncol,2007,106(1):160-163.
[11] 马晓洁,王倩.卵巢癌肿瘤标记物联合检测新进展[J].现代医学，2015,43(3)：395-398.
[12] 刘海伦，程忠平.CA125不同计算方法在卵巢癌筛查，评估及预后方面的作用[J].现代妇产科进展，2016,25(8):636-639.
[13] CHI D S,VENKATRAMA E S,MASSON V,et al.The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage Ⅲ epithelial ovarian carcinoma[J].Gynecol Oncol,2000,77(2):227-231.
[14] 马倩倩,马玲.晚期卵巢癌新辅助化疗前后CA125的变化与减瘤满意率及预后相关性分析[J].现代肿瘤医学，2018,26(6):920-923.
[15] 张国楠,朱熠,黄建鸣.卵巢上皮性癌紫杉醇耐药及治疗策略的思考[J].中华妇产科杂志，2016,51(10)：745-747.
[16] 张国楠,朱熠,黄建鸣.上皮性卵巢癌分子分型和耐药的再认识[J].中国妇产科临床杂志，2017,18(6)：481-483.更正启事《现代医学》2023年第51卷第3期“艾灸刺激足三里对盲插鼻空肠管置管成功率的影响”一文作者单位原为“福建医科大学附属晋江市中医院”，应为“晋江市中医院”。特此更正。本刊编辑部

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录